John V. Talley

Chief Executive Officer at Squarex

John V. Talley

John V. Talley

Chief Executive Officer at Squarex

Overview
Career Highlights

Penwest Pharmaceuticals Co.
Squarex
Izun Pharmaceuticals Corp.

RelSci Relationships

204

Number of Boards

4

Birthday

1956

Age

63

Contact Data
Trying to get in touch with John V. Talley? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals John V. Talley likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer & Interim Chief Financial Officer at Relmada Therapeutics, Inc.

Relationship likelihood: Strong

Former Chief Operating Officer & Chief Medical Officer at Actinium Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chairman, President & Chief Executive Officer at Strategic Imagery LLC

Relationship likelihood: Strong

Chief Financial Officer & Principal Accounting Officer at CorMedix, Inc.

Relationship likelihood: Strong

Chief Executive Officer & Chairman of the Board at Actinium Pharmaceuticals, Inc.

Relationship likelihood: Strong

Independent Agent, Customer Service Specialist & Sales Representative at Aflac, Inc.

Relationship likelihood: Strong

Founder & Partner at Petersen, Waldheim & Cie. GmbH

Relationship likelihood: Strong

Former Vice President-FDA Liaison & Global Strategy at Bristol-Myers Squibb Company

Relationship likelihood: Strong

Former Chief Executive Officer at Quintiles Transnational Corp.

Relationship likelihood: Strong

Partner at Neomed Management (Jersey) Ltd.

Relationship likelihood: Strong

Paths to John V. Talley
Potential Connections via
Relationship Science
You
John V. Talley
Chief Executive Officer at Squarex
Education
B.S. in Chemistry

The University of Connecticut (UConn) is a public research university in Connecticut. Known as a Public Ivy,[3] UConn was founded in 1881 and is a Land Grant and Sea Grant college & member of the Space Grant Consortium. The institution serves more than 30,000 students on its six campuses, including more than 8,000 graduate students in multiple programs.[4] UConn's main campus is in Storrs, Connecticut. The university's president is Susan Herbst.[5] UConn is one of the founding institutions of the Hartford, Connecticut/Springfield, Massachusetts regional economic and cultural partnership alliance known as New England's Knowledge Corridor. UConn is a member of Universitas 21, a global network of 24 research-intensive universities, who work together to foster global citizenship and institutional innovation through research-inspired teaching and learning, student mobility, connecting students and staff, and promote advocacy for internationalisation.[6] UConn is accredited by the New England Association of Schools and Colleges.

M.B.A. in Marketing

Since its inception in 1900, New York University Stern School of Business has been in and of New York City. Founded as the School of Commerce, Finance, and Accounting, the School initially offered training to students for careers in commerce in the burgeoning financial markets of New York City. Today, located in the heart of Greenwich Village with a campus in Westchester, Stern is one of the nation’s premier management education schools and research centers with a broad portfolio of academic programs at the graduate and undergraduate levels. With its global partnerships and engagement in NYU’s global network university, today NYU Stern is not only in and of the city, but also in and of the world.

Career History
Chief Executive Officer
2019 - Current
Chief Executive Officer
2015 - Prior
Chief Executive Officer
Prior - 2013

Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.

Boards & Committees
President, Chief Executive Officer & Director
2012 - 2013

Actinium Pharmaceuticals, Inc. provides development and commercialization of alpha particle immunotherapeutics services. It conducts research based on a patient position for the utilization of actinium-225 and bismuth-213. The company has offices in Oak Ridge, TN and Alexandria, VA. Actinium Pharmaceuticals was founded in 1993 and is headquartered in Florham Park, NJ.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by John V. Talley. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of John V. Talley's profile does not indicate a business or promotional relationship of any kind between RelSci and John V. Talley.